Michael Manzo's most recent trade in Kiora Pharmaceuticals Inc was a trade of 65 Common Stock done at an average price of $2.4 . Disclosure was reported to the exchange on Aug. 3, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 65 | 15,378 (0%) | 0% | 2.4 | 156 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 160 | 15,443 (0%) | 0% | 3.7 | 592 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 155 | 15,603 (0%) | 0% | 4.2 | 649 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 158 | 15,758 (0%) | 0% | 4.1 | 653 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 194 | 15,916 (0%) | 0% | 4.9 | 958 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 192 | 16,110 (0%) | 0% | 5.5 | 1,048 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 990 | 16,302 (0%) | 0% | 6.3 | 6,277 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 17,292 (0%) | 0% | 4.9 | 558 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 97 | 17,498 (0%) | 0% | 3.5 | 340 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 17,595 (0%) | 0% | 3.9 | 380 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 17,693 (0%) | 0% | 3.9 | 382 | Common Stock |
| Kiora Pharmaceuticals Inc | Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 95 | 17,790 (0%) | 0% | 4.1 | 390 | Common Stock |